关于“超声刀治疗”的报告
-
艾媒咨询|2021-2022年中国医美器械产业运行及投资决策分析报告
本报告研究涉及企业/品牌/案例：科医人，复星医药，奇致激光，半岛医疗
伴随着医美市场规模的持续扩大，中国医美器械行业发展前景可期。数据显示，预计2021年中国医美器械市场规模将超过500亿元，同比增长27.8%。从细分赛道来看，近年来，微创和无创已逐渐成为医疗美容的趋势，这就推动了以激光、超声波等能量源为代表的光电类医美器械的发展。从市场格局来看，中国正规医美机构设备的市场份额80%是进口品牌，且中高端市场被飞顿、塞诺龙等海外龙头企业占领。为了改变这一局面，国家及地方先后出台政策鼓励本土医美器械品牌的发展，同时，国有品牌也通过加大自主研发投入和投资并购来扩大市场份额，未来随着下游扩张、需求渗透、技术更新等因素有望加速进口替代。
With the continuous expansion of the medical beauty market, the development prospect of the medical beauty equipment industry in China is promising. According to the data, it is estimated that in 2021, the market size of medical devices in China will exceed 50 billion yuan, with a year-on-year growth of 27.8%. From the perspective of subdivision, in recent years, minimally invasive and non-invasive have gradually become the trend of medical beauty, which promotes the development of photoelectric medical beauty devices represented by laser, ultrasonic and other energy sources. From the perspective of market structure, 80% of the market share of China's regular medical and beauty institutions' equipment is imported brands, and the medium and high-end market is occupied by overseas leading enterprises such as feton and sinolon. In order to change this situation, the state and local governments have successively issued policies to encourage the development of local medical and beauty equipment brands. At the same time, the state-owned brands also expand their market share by increasing independent R & D investment and investment in M & A. in the future, with the downstream expansion, demand penetration, technology update and other factors, it is expected to accelerate the import substitution. -
艾媒咨询|2020年中国细胞生物产业和商业应用分析报告
本报告研究涉及企业/品牌/案例：华夏源、复星医药。
中国细胞生物产业类型呈现多样化趋势，细胞生物临床研究不断深化，伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成，生态圈的完善将在很大限度上推动产业快速发展。数据显示，中国细胞治疗企业融资金额不断增加，从2014年的0.2亿元增长至2019年的28.9亿元。其中，2018年中国细胞治疗企业融资额同比增长706.8%，呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇，同时也有挑战并存。后续产业的发展，将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局，企业也应积极开展生态合作以及更为密切关注市场需求动向，将疗法和新一代医疗创新技术深度融合，实现市场产品多元化与差异化，并推出独特性的精准治疗，从而最大限度地释放产业价值。
The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value. -
艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告
本报告研究涉及企业/品牌/案例：白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业，培力控股,盛实百草,芍花堂,亳药千草,汇群中药
国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research（艾媒咨询）调查显示，有49%的受访用户倾向中医药治疗，与西药基本持平。2018年中国中药材市场规模达1246亿元，同比增长22.40%，在巨大的需求驱动下，中药材种植面积扩大，药材产量将会持续增长。
中药材主要包括上游种植、养殖市场，中游流通市场和下游销售市场三大环节。目前，中药饮片和中成药生产是中药产业的核心，主要包括中药加工，包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面，行业销售收入增速分别在2016和2018年触底回升，华润三九、中国中药、红日药业等上市公司表现良好；中药配方颗粒方面，2006-2016年，中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%，中药配方颗粒或将成为中药饮片加工行业应用广泛的产品；中成药方面，随着国家医改政策的推行，中成药消费需求趋于合理，中成药产量开始回落，但仍处于一个比较高的产量水平，云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。
Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well. -
